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ABSTRACT 
 Sugammadex, a gamma cyclodextrin discovered in 2007, provides a safe 
and effective alternative to drugs currently used in surgery by anesthesiologists.  
A problem in the current practice of anesthesia is the use of Succinylcholine, a 
neuromuscular blocking agent used for the cessation of the patient’s skeletal 
muscle movement.  Succinylcholine is used due to its unique fast onset and short 
duration, ideal for short procedures, difficult intubation scenarios, and rapid 
sequence intubation.  However, it is used cautiously due to several risks such as 
causing myalgia, hyperkalemia, fasciculations, and increasing intracranial, 
intragastric, and intraocular pressure.   
 Sugammadex provides a safer alternative to Succinylcholine because it 
allows immediate reversal of a neuromuscular blockade through a different 
mechanism, which does not lead to harmful adverse effects.  Sugammadex 
works by encapsulating its target muscle relaxant, Rocuronium.  Rocuronium is a 
relatively safer drug than Succinylcholine with a similar time of onset, but a very 
long duration of action.  Since Sugammadex is able to immediately reverse the 
effects of Rocuronium, this combination of Rocuronium and Sugammadex 
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provides the same desired effect as Succinylcholine but without the harmful side 
effects.   
 The current most widely used reversal agent for muscle relaxation is 
Neostigmine.  The problems with Neostigmine are that it can lead to residual 
paralysis and recurarisation if under dosed.  It also produces unwanted 
cholinergic side effects that lead to cardiovascular instability.  Due to this, the 
medical community is in need for a better reversal agent that can both quickly 
and completely reverse muscle paralysis without the need to manage unwanted 
side effects.  Sugammadex is able to address both the problems of 
Succinylcholine and Neostigmine. 
Studies have shown Sugammadex to provide a faster, safer, and more 
predictable reversal of Rocuronium – induced neuromuscular blockade than 
Neostigmine.  Sugammadex has shown to also achieve faster recovery from 
Rocuronium – induced muscle paralysis than the fast spontaneous recovery of 
Succinylcholine.  With no serious adverse effects observed in these studies, the 
data supports the use of Sugammadex and its potential to replace the current 
standards of practice with Succinylcholine and Neostigmine.  Furthermore, high 
dosage of Sugammadex has shown to be capable of immediately reversing 
profound neuromuscular blockades, an ability that no reversal drug currently in 
the market possesses.  This enables the anesthesiologist to provide optimal 
muscle relaxation for the surgeon throughout the operation without the concern 
of being unable to reverse the patient in a timely manner. 
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Studies on multiple patient population groups do not show any serious 
adverse effects are linked to using Sugammadex.  There have been incidences 
of drug induced QTc prolongation in cardiac patients, but its cause was not 
determined to be related solely with Sugammadex.  Sugammadex has shown to 
be the safer reversal agent compared to Neostigmine in cardiac, pulmonary, and 
renal patients.   
One problem that prevents the routine use of Sugammadex is its cost.  
The cost is significantly higher than Neostigmine.  This cost is justified, however, 
due to staff costs saved from a faster patient recovery and shorter stay in the 
hospital.  Therefore, while Sugammadex is definitely warranted over 
Succinylcholine due to its safety profile, its use over Neostigmine is dependent 
on each healthcare facility.  While Sugammadex is currently under review by the 
Food and Drug Administration, it will evolve the practice of anesthesia if allowed 
into the United States market.  
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Introduction 
The practice of anesthesia originated in ancient times, and is a specialty 
undergoing constant evolution especially in the mid-nineteenth century.  Ancient 
civilizations had long used coco leaves, opium poppy, mandrake root, and 
alcohol as anesthetics in order to allow surgeons to operate in tolerable 
conditions regarding their patients.  Due to advances in the pharmaceutical 
industry and a better understanding of human physiology, various drugs are now 
administered to achieve the desired conditions for the surgeon.  Prior to these 
advancements in the past decade, modern surgery was hampered not only by 
poor understanding of pathology, anatomy, and aseptic technique, but it also 
lacked reliable and safe anesthetics and anesthetic technique.  The practice of 
anesthesia evolved first with development of inhalation anesthesia affecting the 
entire autonomic nervous system of the body.  This was followed by anesthetics, 
which have effects locally or at a specific region of the body by targeting local 
conduction of nerves cells or segments of the spinal tract.  Finally, 
pharmaceutical companies have now developed a wide spectrum of safe 
intravenous anesthetics with various durations, times of onset, and mechanisms 
of action that accommodate various scenarios of the patient and surgical 
procedure. 
Anesthetizing a patient for preparation of surgery can be categorized as 
either achieving conscious sedation, regional anesthesia, or unconscious 
sedation, with the latter termed as general anesthesia.  Conscious sedation the 
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anesthetic technique utilized as a standard for minor procedures such as 
colonoscopies, surgeries on the extremities, and other minimally invasive 
operations.  Regional anesthesia involves blockage of pain to a specific portion 
of the body in either a conscious or unconscious patient, and it is the standard for 
parturition since only the midsection is required for anesthetizing without 
compromising the mother’s airway and memory of the event.  General 
anesthesia is the main form of anesthetic technique used to provide the optimum 
conditions for the surgeon in general, cardiothoracic, neurosurgery, plastic, 
genitourinary, ophthalmic, otorhinolaryngologic, orthopedic, trauma, and pediatric 
surgery. 
General anesthesia involves the cessation of the patient’s memory and 
anxiety, consciousness, pain sensation, and skeletal muscle activity.  Amnesia, 
sedation, analgesia, and paralysis are achieved by benzodiazepines, hypnotics, 
analgesics, and skeletal muscle relaxants, respectively (Morgan, 2006).  
Furthermore, total control of the patient’s autonomous nervous system is given to 
the anesthetist by manipulating patient’s cardiovascular functions with 
intravenous medications targeting the body’s alpha and beta receptors, as well 
as specific ion channels in the heart and vasculature.  Once the patient is under 
general anesthesia, the anesthetist will then be able to perform intubation in 
order to maintain a patent airway, as well as controlling the oxygenation, 
ventilation, and concentration of inhalational anesthetics that the patient receives. 
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 The cessation of skeletal muscle movement in general anesthesia is 
achieved by administering a neuromuscular blocking agent.  The anesthetic 
drugs currently used for muscle paralysis and reversal of paralysis have many 
adverse effects and limitations.  Currently, there is still a need for a fast, effective, 
and relatively safe drug to provide immediate paralysis and recovery of a 
patient’s muscles for the various clinical scenarios that the surgeon or 
anesthesiologist must face from patient to patient. 
Neuromuscular blocking agents, for the paralysis of skeletal muscle, are 
indicated for various purposes in the surgical setting.  When intubating a patient, 
they are necessary for relaxing the vocal chords in order to gain access to the 
trachea and for intubating the patient without the hindrance of coughing and 
gagging reflexes.  During surgery, they are necessary for the cessation of motor 
reflexes and decreasing skeletal muscle tone, so that the surgeon is able to 
operate and manipulate the patient’s anatomy without movement or resistance.  
Neuromuscular blocking agents work by targeting the ACh receptors on the 
motor end plate in the neuromuscular junction.  Similar to ACh, all neuromuscular 
blocking agents are quaternary ammonium compounds, where their positively 
charged nitrogen exhibits great affinity to the nicotinic ACh receptors.  Since 
these agents are not metabolized by the enzyme acetylcholinesterase, they 
remain on the ACh receptors and prevent ACh from binding to the receptor.  As a 
result, the normal response of ACh induced sodium ion channel opening, end-
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plate potential generation, and action potential transmission for skeletal muscle 
depolarization is prevented (Morgan, 2006). 
The two most widely used neuromuscular blocking agents are 
Succinylcholine and Rocuronium.  While both agents prevent ACh induced 
skeletal muscle depolarization, they are in two separate categories involving 
different mechanisms of action, times of onset, durations, advantages, and 
disadvantages.  Rocuronium Bromide is a non-depolarizing muscle relaxant.  
Non-depolarizing muscle relaxants bind to the ACh receptor, but are incapable of 
inducing a conformational change of the receptor that is necessary for opening of 
the calcium ion channels.  Due to its characteristics of preventing conformational 
change of the receptor, neuromuscular blockade occurs even when only one 
alpha subunit is blocked and the other alpha subunit is bound to ACh (Naguib, et 
al., 2007).  Rocuronium is administered intravenously as a concentration of 
10mg/mL and with a patient dose of 0.8 mg/kg in order to achieve sufficient 
paralysis for intubation.  Its onset of action is 90 seconds and its duration of 
action ranges from 35 to 75 minutes depending on the time it takes for 
Rocuronium to diffuse away from the neuromuscular junction and also the ability 
of the body to metabolize it within the plasma and liver by pseudocholinesterase, 
a non-specific cholinesterase found in the plasma and liver but not at the 
neuromuscular junction (Morgan, 2006). 
Succinylcholine is a depolarizing muscle relaxant, and it is the only 
available drug that falls in this other category of muscle relaxants.  It is unique 
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because it resembles ACh very closely, and it is therefore able to bind the ACh 
receptor and generate a muscle action potential.  Unlike ACh however, this drug 
is not metabolized by acetylcholinesterase, and it does not rapidly diffuse away 
from the synaptic cleft.  This results in a prolonged motor end-plate 
depolarization without allowing repolarization of the end-plate as long as it 
remains concentrated in the synaptic cleft and continues to bind ACh receptors.  
Since the lower gate opening of the sodium ion channels on the end-plate is time 
limited, it will eventually close and cannot reopen until repolarization occurs.  An 
action potential cannot be regenerated because the constant binding of this 
depolarizing muscle relaxant prevents repolarization, and ACh continues to be 
competitively inhibited by it.  Consequently, the observed effect is an initial period 
of muscle fasciculation, or muscle twitches, followed by a period of muscle 
paralysis. 
Succinylcholine is administered intravenously as a concentration of 20 
mg/mL at a patient dose of 1 mg/kg for intubation.  Its onset of action is 30 
seconds and its duration of action ranges from 2 to 3 minutes depending on the 
normal body’s pseudocholinesterase concentration and ability when the drug 
diffuses away from the synaptic cleft and enters circulation (Morgan, 2006).  
Although Succinylcholine is a relatively safe drug, it has many potential 
complications. 
The first risk of using Succinylcholine is its effects on the cardiovascular 
system due to its close resemblance to ACh.  In addition to affecting the 
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cholinergic receptors at the neuromuscular junction, Succinylcholine stimulates 
all ACh receptors in the body.  As a result of stimulating the nicotinic receptors in 
the parasympathetic, sympathetic ganglia and the muscarinic receptors in the SA 
node of the heart, the blood pressure, heart rate, heart contractility, and 
circulating catecholamine levels will all increase at high doses of the drug.  Low 
doses of Succinylcholine, however, can produce negative chronotropic and 
inotropic effects, which makes the pediatric patient highly susceptible to 
bradycardia (Weisberg, et al., 2008).  To circumnavigate this unwarranted effect, 
intravenous atropine is normally given prophylactically to children.  The 
anticholinergic effects of atropine causes an increase in heart rate, which 
negates the negative chronotropic effects of Succinylcholine.  If bradycardia is 
left untreated, arrhythmias such as nodal bradycardia and ventricular ectopy 
have been reported in the past (Weisberg, 2008; Ramamoorthy, et al., 2011). 
The second risk of using Succinylcholine is its effects from the initial 
muscle contracts that are triggered from its depolarizing effects.  The visible 
motor contractions, called fasciculations, can lead to an increased incidence of 
post-operative myalgia.  Myalgia, or muscle pain, is thought to be due to the 
initial unsynchronized muscle contractions.  When this event is observed, 
myoglobinemia and increased serum creatine kinase levels can be detected, 
which indicates occurrence of rhabdomyolysis, or muscle wasting.  
Prophylactically, the practice of administering NSAIDS peri-operatively has 
shown to reduce the incidence and severity of myalgias.  Other muscular 
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complications observed following the administering of Succinylcholine include 
masseter rigidity.  Transient increases in muscle tone of the masseter muscles 
make opening the mouth for laryngoscopy and intubation extremely difficult 
(Weisberg, 2008). 
The third and most common risk of using Succinylcholine is inducing 
hyperkalemia to the patient.  In a normal patient, potassium is released from the 
skeletal muscle cells during the drug-induced depolarizations resulting in an 
elevation of serum potassium levels by 0.5 mEq/L.  Since normal potassium 
levels of patients range from 3.5 – 5.3 mEq/L, this elevation would be 
insignificant in patients.  However, this can be life-threatening in patients with 
burn injury, massive trauma, neuropathies such as Guillain-Barre syndrome and 
Parkinson’s Disease, and myopathies such as Duchenne’s muscular dystrophy 
(Ramamoorthy, et al., 2011).  Particularly in denervation injuries such as severe 
burns and massive trauma, the body expresses immature isoforms of the ACh 
receptor inside and outside of the neuromuscular junction, called extra-junctional 
receptors.  As a result of administering Succinylcholine and its binding to these 
receptors, wide depolarization and extensive potassium release will occur.  The 
expression of extra-junctional receptors appear after 48 hours of burn and 
trauma patients, and Succinylcholine is therefore contra-indicated in these 
patients if admitted to the hospital over 2 days of the incident.  
As a result of severe hyperkalemia, defined as a potassium serum level 
over 7.0 mEq/L, the anesthetized patient may exhibit paresthesia and muscle 
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weakness leading to flaccid paralysis, metabolic acidosis, and cardiac 
arrhythmias.  Cardiac complications arise due to depolarization of its cell 
membrane, slowing of ventricular conduction, and shortening of action potential 
duration by effects of hyperkalemia.  In order of their appearance in an untreated 
patient, ECG will show peaked T waves, QRS complex widening, loss of the P 
wave, ventricular fibrillation, and finally asystole leading to cardiac arrest.  The 
anesthetist must be vigilant in order to detect initial signs of hyperkalemia in 
highly susceptible patients, following the administration of Succinylcholine, by 
monitoring ECG trends and obtaining a Chem 7 from the serum if needed.  
Treating mild to moderate hyperkalemia with administering calcium, insulin with 
glucose, bicarbonate, or epinephrine is necessary to prevent the effects of 
severe hyperkalemia (Weisberg, 2008).   
The fourth risk of administering Succinylcholine to a patient is its effects of 
elevating intra-ocular, intra-gastric, and intra-cranial pressure.  The extra-ocular 
muscles of the eye are different from other striated muscles due to having 
multiple motor end-plates on each cell for minute and precise movements.  
Prolonged membrane depolarization and contraction of these muscles after 
administering Succinylcholine will transiently raise intraocular pressure and 
compromise a patient with an eye injury.  Due to this, patients with glaucoma and 
patients undergoing eye surgery are both contra-indications to using this drug 
(Morgan, 2006).   
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The increase in intra-gastric pressure is due to abdominal wall muscle 
fasciculations.  However, there is no high risk of gastric reflux and pulmonary 
aspiration due to an increase in the tone of the lower esophageal sphincter as 
well.  Succinylcholine is therefore contra-indicated in patients with Scleroderma 
due to esophageal dysmotility and incompetence of the lower esophageal 
sphincter, which is found in all types of Scleroderma.  Lastly, elevated intra-
cranial pressure is due to increased cerebral blood flow after giving the drug.  
While the effects are also transient and mild, the drug is contra-indicated in 
patients with a closed-head injury for this reason (Morgan, 2006).   
The fifth and final risk of administering Succinylcholine is both the rarest 
and most fatal.  Succinylcholine and inhalational anesthetics both are triggering 
agents for Malignant Hyperthermia.  In 80% of reported cases, both 
Succinylcholine and an inhalational anesthetic were used.  Since inhalational 
anesthetics are almost always used in surgeries with general anesthesia, 
Malignant Hyperthermia is always a concern in the back of most anesthetists’ 
minds when choosing to use Succinylcholine over a non-depolarizing muscle 
relaxant such as Rocuronium.  Malignant Hyperthermia is a rare myopathy 
characterized by an acute hyper-metabolic state which can present either during 
or hours after general anesthesia.   
The anesthetist must watch for its initial signs of masseter muscle rigidity, 
tachycardia, increased carbon dioxide production, and tachypnea.  While two or 
more of these signs greatly increases the likelihood of its occurrence, it is definite 
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when there are signs of hypertension, metabolic acidosis, arrhythmias, 
rhabdomyolysis, and hyperthermia characterized by an increase of up to 1˚C of 
core body temperature every 5 minutes.  The uncontrolled release of intracellular 
calcium from sarcoplasmic reticulum removes the inhibition of troponin, leading 
to intense muscle contractions and wasting.  As muscle breaks down, potassium 
efflux from muscle cells causes hyperkalemia.  The increases of carbon dioxide 
indicate a hyper-metabolic state that will lead to severe lactic acidosis and 
hyperthermia.  In the 1970s when there was no treatment protocol, this event had 
a mortality rate of over 80%.  However, current aggressive treatment protocols 
with the immediate use of the intravenous drug Dantrolene, ventilation with 100% 
oxygen, ice packs, cooling blankets, iced saline lavage, and/or cold dialysis have 
lowered the risk of death to 5-30%.  The osmotic diuretic Mannitol is also given to 
prevent acute renal failure from myoglobinuria if the patient survives.  Other 
complications after surviving an episode of Malignant Hyperthermia include 
disseminated intravascular coagulation, cerebral edema with seizures, and acute 
hepatic failure (Morgan, 2006). 
With all these risks of using Succinylcholine, it is nevertheless the only 
muscle relaxing agent with the fast onset time of 30 seconds combined with a 
short duration of 2 to 3 minutes.  The fastest onset time for a non-depolarizing 
muscle relaxant is 60 – 90 seconds with Rocuronium, but the high dose that is 
required to achieve close to 60 seconds will result in a long duration of action up 
to 75 minutes.  The shortest acting non-depolarizing muscle relaxing agent 
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available clinically is Mivacurium, with a duration ranging from around 10 minutes 
in children, 20 minutes in adults, and 30 minutes in elderly.  However, the 
anesthetist must wait an average of 2 minutes for the onset of Mivacurium to 
reach conditions suitable for intubation.  In these comparisons, it is apparent that 
the unique qualities of Succinylcholine make it ideal for patients that are 
characterized with full stomachs or with difficult airways, where a fast and short 
acting muscle relaxant is desired.   
Normally before most elective surgeries, patients are required to stop 
eating and drinking 8 hours and 2 hours before the time of surgery, respectively.  
When these patients arrive in the operating room, they are considered to have an 
empty stomach and routine surgery is allowed to commence.  This is because 
when consciousness is lost after induction of general anesthesia, a patient 
without an empty stomach may regurgitate gastric material, which may become 
aspirated into the lungs and cause severe inflammation to the lung tissue.  This 
is called aspiration pneumonitis, and it is often fatal if either the gastric contents 
have a pH acidity less than 2.5 or if the aspirated gastric contents exceed 25 mL 
(Morgan, 2006).   
The regurgitation occurs due to a shift of the pressure gradient at the 
esophagogastric junction.  The lower esophageal sphincter normally maintains a 
tone where its closing pressure exceeds the intra-gastric pressure.  When the 
conscious level is depressed in the anesthetized patient, the tone of the sphincter 
will decrease, and regurgitation will occur if intra-gastric pressures exceed the 
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closing pressure of the sphincter.  The risk of regurgitation is even greater if the 
intra-gastric pressure is further increased by presence of food or liquid, obesity, 
intra-abdominal swelling, hiatal hernia, 3rd trimester pregnancy, and the lithotomy 
position where the supine patient’s legs are raised.  Pregnancy increases the risk 
of regurgitation even further because the hormonal changes in the female patient 
causes a decrease in the efficiency of the sphincter.  Some anesthetic drugs also 
decrease the tone of the sphincter such as opioids, which are commonly used for 
analgesia and pain management in almost all surgeries.  This is why a morbidly 
obese patient, a pregnant patient, and a patient undergoing emergency surgery 
are all considered full stomach.  In these scenarios, the anesthetist must utilize 
rapid sequence induction, where Succinylcholine is often used for its fast onset. 
Rapid sequence induction involves taking every precaution to prevent 
regurgitation and limiting the time between when a patient is anesthetized and 
when the patient’s airway is secured and protected via intubation.  A variety of 
laryngoscopes and endotracheal tubes are prepared in advance, and a smaller 
tube is often used first to maximize the chances of an easy intubation.  Normally, 
the patient is given positive pressure ventilation using the bag and facemask 
after inducing unconsciousness to ensure that the anesthetist is able to ventilate 
the patient before administering the muscle relaxant and eliminating the patient’s 
ability to spontaneously breathe.  However, delivering positive pressure is contra-
indicated in the full stomach patient.  Therefore, the muscle relaxant is 
administered immediately after the induction agent, an anesthetic used to put the 
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patient to sleep.  The patient, as a result, will be immediately ready for intubation 
when unconscious and when the lower esophageal sphincter becomes 
depressed.  Since most induction agents such as Propofol and Ketamine have 
an onset time of under 40 seconds, Succinylcholine is commonly used due to 
having a similar time of onset.  The time between induction and intubation must 
be minimized because in addition to risks of regurgitation, the induced patient is 
also unable to breathe spontaneously.  The anesthetist is unable to deliver 
positive pressure ventilation via facemask during this time because the pressure 
will travel down both the trachea and esophagus, potentially triggering 
regurgitation.  Therefore if Rocuronium is used for intubation, there will be around 
60 seconds of inactivity where the patient is asleep and unable to breathe 
spontaneously, and the anesthetist is unable to intubate until Rocuronium relaxes 
the vocal chords.   
The most common usage of Succinylcholine by anesthetists is for 
intubating the difficult airway patient.  A patient is considered to have a difficult 
airway if the conventionally trained anesthetist experiences difficulty with 
facemask ventilation, difficulty with tracheal intubation, or both.  Difficulty with 
intubation commonly involves being unable to visualize any portion of the vocal 
chords resulting in a failed tracheal intubation, where the endotracheal tube is 
accidentally placed into the esophagus instead of the trachea.   
The risk of a difficult airway patient is often determined from the patient’s 
medical history and a physical examination by the Anesthesiologist before the 
 14 
surgery.  Common conditions associated with difficult airways include anatomical 
hindrances, anatomical restrictions, and obesity.  Hindrances include tumors in 
the airway such as Cystic Hygroma, hemangioma, and hematoma.  Infections 
lead to hindrances such as submandibular abscess, peritonsillar abscess, and 
epiglottitis. Anatomic variations such as micrognathia, prognathia, and prominent 
upper incisors will also cause hindrances (Morgan, 2006).  Foreign bodies lodged 
in the airway will also cause hindrances.  Obesity, short and thick necks, and 
large tongues are the most common determinants of a difficult airway because a 
likely history of sleep apnea will prove to be an issue when delivering oxygen 
through the bag and facemask or when the patient attempts to breathe 
spontaneously.    
When the anesthesiologist attempts to intubate the difficult airway, the 
difficult airway algorithm is used, implemented by the American Society of 
Anesthesiology.  The algorithm tells the anesthesiologist to re-oxygenate the 
patient with a bag and facemask after a failed intubation before the next few 
attempts.  After multiple failures, the anesthesiologist must consider advanced 
techniques of intubation including the use of a glidescope, light wand, laryngeal 
mask airway, or fiberoptic intubation depending on the anesthesiologist’s 
preference and expertise.  When failure ensues, the anesthesiologist should 
allow the induction agent and muscle relaxing agent to wear off, and intubate the 
patient when awake.   If awake intubation fails or if at any time the 
anesthesiologist is unable to oxygenate the patient with the facemask, a common 
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risk for patients with sleep apnea, the anesthesiologist must proceed with an 
emergency intubation, which involves invasive procedures such as a 
tracheotomy.   
A patient is informed after the pre-operative examination that he/she has a 
difficult airway and if needed, the anesthesiologist must intubate the patient 
consciously sedated or in the worst case scenario, a tracheotomy.  The benefits 
of the awake patient is that the patient maintains his/her own airway and the 
tongue does not fall back and impede the airflow and visualization in the 
oropharynx as much as an unconscious patient.  This eliminates both the time 
limitations and visual hindrances that the anesthesiologist would face when 
intubating a patient after induction.   
The advantage of Succinylcholine for intubating a difficult airway patient is 
its short duration of effect of 2 to 3 minutes.  This allows the anesthesiologist the 
option to decide if the patient should be re-administered with Succinylcholine for 
further intubation attempts or if the patient needs to awaken and breathe 
spontaneously.  The latter option is often the case when the anesthesiologist has 
difficulty with oxygenating the induced patient with the bag and facemask due to 
the anatomical obstructions aforementioned.  The disadvantage of Rocuronium 
or the short acting Mivacurium is their duration of over 10 minutes.  This makes 
Succinylcholine superior over the non-depolarizing muscle relaxants because its 
duration falls under the time of safe apnea. 
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The time of safe apnea is the time it takes for the pre-oxygenated apneic 
patient to fall under 90% oxygen saturation on the pulse oximeter.  According to 
the oxygen-hemoglobin saturation curve, 90% oxyhemoglobin saturation 
indicates a 70 mmHg partial pressure of oxygen in the arterial blood.  As the 
partial pressure of oxygen continues to decrease in the apneic patient, the 
saturation of oxyhemoglobin begins to exponentially decrease after this point due 
to the sigmoidal nature of the curve.  At any time this occurs to the un-intubated 
patient, the anesthesiologist must aggressively establish an airway for 
oxygenation, which includes the use of oral and nasal airway tools, laryngeal 
mask airways, or performing tracheotomy in the cyanotic patient.   
According to a study on how obesity affects the time of safe apnea, results 
indicate that compared to the average time of 6.1 minutes in normal patients, the 
time it took an obese apneic patient to fall to 90% saturation was 4.1 minutes and 
2.7 minutes in a morbidly obese apneic patient (Gaszynski, et al., 2011).  This is 
largely due to the increased metabolic oxygen demand and substantially 
decreased functional residual capacity of the obese patient.  The Succinylcholine 
is therefore considered a double-edged sword due to being the only clinically 
safe product in the market able to quickly paralyze and un-paralyze the patient, 
but listed with several contra-indications and risks of use.   
The practice of Anesthesiology had once again evolved with the discovery 
of the drug Sugammadex at the Newhouse research site in Scotland in 2008.  
Sugammadex is an agent used for the reversal of neuromuscular blockade by 
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the muscle relaxing agent Rocuronium.  This is possible because of its modified 
gamma cyclodextrin chemical structure, which is able to exert a chelating action 
that effectively encapsulates and binds the aminosteroid non-depolarizing muscle 
relaxants, Rocuronium, Vecuronium, and Pancuronium.  This effectively 
eliminates their ability to bind nicotinic receptors.  Selectively binding and 
terminating the effects of a muscle relaxing agent is an advancement to our 
current standards of practice because muscle relaxant reversal is currently 
achieved indirectly by means of inhibiting acetylcholinesterase (Duvaldestin, et 
al., 2010).   
When an operation is nearing completion and the surgeon begins to 
suture, the anesthesiologist begins protocols for extubation and awakening the 
patient.  As a criterion before extubating the endotracheal tube, the anesthetist 
must allow the patient to spontaneously breathe via the endotracheal tube by 
means of reversing the effects of the long acting non-depolarizing muscle 
relaxants.  This is done by administering either Neostigmine or Edrophonium, 
intravenous agents for inhibiting acetylcholinesterase.  By selectively binding to 
acetylcholinesterase, these agents indirectly increase the amount of 
acetylcholine available in the neuromuscular junction.  Since non-depolarizing 
muscle relaxants work by direct inhibition of acetylcholine, the level of inhibition 
decreases as a result of increasing the available substrate.   
There are two disadvantages with using these two anticholinesterase 
agents.  Firstly, they do not exclusively act at the neuromuscular junction, but 
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rather at all cholinergic receptor sites.  This includes the entire parasympathetic 
nervous system and parts of the sympathetic nervous system, specifically the 
sympathetic ganglions, adrenal medulla, and sweat glands.  A generalized 
overabundance of acetylcholine will desirably activate the nicotinic receptors in 
skeletal muscle, but it will also activate the muscarinic receptors in the end-organ 
effector cells of bronchial smooth muscle, salivary glands, and the sinoatrial node 
of the heart (Illman, et al., 2010).  As a result, muscle relaxant reversal will be 
accompanied by a vagal-like bradycardia that can progress to sinus arrest, 
bronchospasms, increased respiratory tract secretions, and undesired effects in 
the gastrointestinal tract including intestinal spasms, nausea, vomiting, and fecal 
incontinence.  The standard of anesthetic practice is currently to administer an 
anti-muscarinic agent such as Glycopyrrolate or Atropine, in order to negate the 
marked increases in muscarinic receptor activation caused by Neostigmine or 
Edrophonium.  These agents bind to and competitively inhibit muscarinic 
receptors, in order to mask the muscarinic effects of increasing acetylcholine on 
the sympathetic and parasympathetic autonomous nervous systems, without 
affecting its effect at the neuromuscular junction. 
The second drawback of anticholinesterase agents is that the required 
dose depends on the degree of neuromuscular blockage due to the relationship 
of substrate and inhibitor concentration in competitive inhibition.  Moreover, no 
amount of cholinesterase inhibitor can immediately reverse a complete 
neuromuscular block.  This translates to time that the anesthetist must wait to 
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pass, normally 10 to 20 minutes, before administering this type of muscle 
relaxant reversal agent (Illman, et al., 2010).  The appropriate time to administer 
these reversal agents is determined by frequent use of a peripheral nerve 
stimulator.  An elicited muscle twitch or tetanus indicates a muscle blockage 
between 75 – 95%, which is suitable for reversal.  In emergency or difficult 
airway scenarios, where the anesthetist is unable to intubate or oxygenate the 
patient, the time needed for effective reversal and return to spontaneous 
breathing greatly exceeds the time of safe apnea (Sorensen, et al., 2012).   
Sugammadex is unique because it is the first drug that can provide 
reversal of a profound neuromuscular block, and it can provide an immediate 
reversal when required.  Unlike Neostigmine and Edrophonium, this is 
accomplished without inhibiting acetylcholinesterase.  Therefore, the cost and 
labor of administering a muscarinic receptor antagonist, Atropine or 
Glycopyrrolate, to negate an unwarranted decrease in heart rate are also 
avoided.  Sugammadex has a concentration of 100 mg/mL, and it has a varying 
recommended patient dose depending on the level of neuromuscular blockade 
from Rocuronium, Vecuronium, or Pancuronium.   
The presence of an induced twitch or tetanus with the nerve stimulator 
indicates shallow blockade, and this only requires a dose of 2.0 mg/kg for 
complete reversal.  This is also when the conventional muscle relaxant reversal 
agents are used, after a period of 10 to 30 minutes following the administration of 
the muscle relaxant depending on the patient and the drug used.  In a profound 
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neuromuscular blockade, there are no twitches or sustained tetanus observed.  
However, the patient will exhibit 1 to 2 post-tetanic twitches.  These are twitches 
that are induced after delivering 5 seconds of sustained nerve stimulation.  The 
absence of tetanus and appearance of post-tetanic twitches indicate a profound 
neuromuscular blockade, and our conventional muscle relaxant reversal agents 
are unable to reverse (Mirakhur, 2009).  However, Sugammadex is capable of 
reversing this profound neuromuscular blockade at a recommended dose of 4.0 
mg/kg.  Lastly, Sugammadex is able to provide immediate reversal of 
Rocuronium due to its high affinity for Rocuronium compared to Vecuronium and 
Pancuronium.  After 3 minutes of administering Rocuronium, Sugammadex is 
capable of a complete reversal at a recommended dose of 16.0 mg/kg (Naguib, 
et al., 2007).  Aside from Rocuronium, there is currently no data to support the 
use of Sugammadex for immediate reversal following Vecuronium or 
Pancuronium induced blockades. 
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Specific Aims 
 This review will address a problem in the medical field, specifically in the 
field of Anesthesiology, which impacts all patients undergoing surgery with 
anesthesia, as well as licensed providers of anesthesia.  I undertook this study 
because of my background in pharmaceutical sciences and clinical training in 
anesthesia.  Having performed countless intubations and administrations of 
Succinylcholine in my clinical experiences, I understand how important 
Sugammadex will be for the patient and provider.  Sugammadex is currently 
approved for use in Europe, United Kingdoms, and Australia.  Therefore, I am 
interested in performing a complete analysis of this drug, and whether or not it 
should be implemented in the United States. 
 This review will present all aspects of the drug Sugammadex including its 
chemical structure and composition, mechanism of action, pharmacokinetics, 
pharmacodynamics, safety profile, and cost-benefit analysis.  In addition, 
published studies and case reports on the effects of Sugammadex on specific 
patient groups and specific surgical procedures will also be presented.  I will 
determine both advantages and disadvantages of using Sugammadex, as well as 
determining whether it should replace any currently used anesthetics involved in 
neuromuscular blockade.  My hypothesis is that Sugammadex is much safer to 
use than Succinylcholine, but due to high costs, it will not replace our 
conventional muscle relaxant reversal agents as the standard for routine use. 
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Presentation of Published Data 
 Sugammadex is a modified gamma cyclodextrin, a cyclic oligosaccharide 
composed of dextrose units.  The gamma form has 8 dextrose subunits, a 
hydrophobic interior, and a hydrophilic exterior.  By modifying every 6th carbon 
hydroxyl group with substitution of a carboxyl thioether linkage, the hydrophilic 
peripheral gains three advantages.  Firstly, due to the negatively charge on the 
modified groups, Sugammadex will bind electrostatically to the positively charged 
ammonium groups of aminosteroidal neuromuscular relaxing agents with great 
affinity.  Secondly, the longer tail of these modified peripheral groups allows 
greater surface area where these electrostatic interactions can occur.  This 
allows the molecule to completely encapsulate the substrate.  Lastly, the added 
negatively charged carboxyl groups increase the aqueous solubility of the 
molecule (Adam, et al., 2012). 
 The mechanism of action of Sugammadex reversal of Rocuronium and 
other aminosteroidal neuromuscular relaxing agents is by means of 
encapsulation and mass diffusion of the substrate from the neuromuscular 
junctions to the plasma.  Early studies by Bom and colleagues showed the 
encapsulation process to be due to thermodynamic attractions at a one-to-one 
binding ratio.  These attractions include electrostatic interactions, hydrogen 
bonding, hydrophobic interactions, and Van Der Waals interactions.  The 
lipophilic cavity, where the aminosteroidal substrates become trapped in, is in 
close contact of all four steroidal rings of the substrate.  In addition, the carboxyl 
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group’s attraction for Rocuronium’s tertiary ammonium results in higher affinity 
compared to other aminosteroidal neuromuscular relaxing agents (Bom, et al., 
2002). 
 Encapsulation occurs mainly in the plasma, and it has two effects on 
Rocuronium.  First, it prevents the encapsulated Rocuronium to diffuse into the 
neuromuscular junction and bind to the nicotinic receptors.  Second, it causes a 
drastic decrease in concentration of unbound Rocuronium in the plasma.  This 
causes a diffusion of Rocuronium down its concentration gradient away from the 
neuromuscular junction.  Any molecules bound to nicotinic receptors are also 
rapidly drawn away and encapsulated in the plasma (Baldo, et al., 2011).  This 
results in a rapid reversal of any depth of neuromuscular blockade.   
Sugammadex is selective for steroidal neuromuscular relaxing agents 
only.  Evidently, non-steroidal agents such as Succinylcholine and Cisatracurium 
both have a Ka value that is 1000 times less than the steroidal agents.  The Ka 
value, measured in millions per one molarity, for Rocuronium, Vecuronium, and 
Pancuronium are 25.0, 10.0, and 2.6, respectively (Duvaldestin, et al., 2010).  
Therefore, Rocuronium will be the main neuromuscular relaxing agent for 
discussion because it is both the most selective for Sugammadex and it is the 
most clinically used compared to other steroidal neuromuscular relaxing agents. 
Following the initial discovery of Sugammadex and assessment on 
animals, an Investigational New Drug application (IND) is submitted to the Food 
and Drug Administration (FDA).  Once approved, clinical trials begin and proceed 
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in four phases.  Phase I of clinical trials are studies performed on healthy human 
individuals, usually a sample size under 100, to assess the therapeutic effect, 
potency, dosage ranges, and identify possible side effects.  Phase II trials 
continues to assess these drug characteristics, but there are multiple studies 
performed with sample sizes over 100 human participants each.  Phase III trials 
use a sample size over 1000 subjects to further refine these drug parameters.  In 
addition, these studies try to find potential drug-drug interactions, drug efficacy in 
different patient populations, and effectiveness compared to conventional 
treatments.  Once the FDA approves the findings of Phase III trials, the drug is 
normally submitted to the FDA for marketability.  Phase IV is the post marketing 
surveillance of the drug to explore its long term benefits and risks when used on 
a large scale.  The sample size of these studies is generally over 10,000 
subjects. 
The approval of IND submission of Sugammadex occurred in 2004 after 
initial testing on animals showed successful results in its ability to reverse NMBA 
effects.  Gijsenbergh and his colleagues were the first to perform Phase I studies 
of Sugammadex.  29 healthy male volunteers received either Sugammadex or a 
placebo, and the time and level of reversal from Rocuronium induced paralysis 
were recorded.  Results showed that reversal occurred after 1 minute following 
Sugammadex administration at a dose of 8.0 mg/kg, compared to 52 minutes 
with the placebo.  It was concluded that Sugammadex was both safe and 
effective in these individuals (Gijsenbergh, et al., 2005).  A similar study also 
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came to this conclusion when Sugammadex provided complete reversal of 
Rocuronium or Vecuronium induced muscle paralysis in 16 individuals (Cammu, 
et al., 2008). 
Phase II and III clinical trials were conducted to find dosage and safety 
margins of Sugammadex in both shallow and profound neuromuscular blockage.  
While Phase II studies concentrated on dose-finding and safety, Phase III also 
included comparative studies, where Sugammadex was cross analyzed with 
conventional reversal agents such as Neostigmine and Edrophonium.  The level 
of neuromuscular block and the degree of reversal are measured by performing a 
train-of-four using a nerve stimulator.  The train-of-four stimulation is a series of 
nerve stimulations, where the number and intensity of muscle twitch responses 
are recorded.  A shallow block is defined as 2 twitches out of 4, and a profound 
block is defined as no twitches out of 4, but the presence of 1 to 2 post-tetanic 
twitches (Naguib, et al., 2007).  On the other hand, a full reversal of 
neuromuscular blockade is defined as the presence of all 4 twitches with the 4th 
twitch being at least 90% the magnitude of the 1st twitch.  This is due to the fact 
that a continuous decrease in twitch magnitude is still indicative of some level of 
block despite the presence of all four twitches. 
The inclusion criteria of patients for Phase II and III trials were adult 
patients, with written consent, undergoing general anesthesia requiring 
neuromuscular blocking agents for surgical procedures in the supine position.  
These patients ranged from ASA class I to II, II or IV depending on the study.  
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The ASA ranking is the standard for anesthesiologists in determining how healthy 
a patient is for surgery and general anesthesia.  The exclusion criteria for Phase 
II and III trials were patients with neuromuscular disorders, pregnancy, significant 
renal dysfunction, history of malignant hypothermia, allergies to any of the drugs 
used in general anesthesia, and medications currently taken that are known to 
interfere with neuromuscular relaxing agents.   
Multiple Phase II studies were conducted on the safety and efficacy of 
Sugammadex in reversal of various steroidal neuromuscular blocking agents.  In 
several studies of Rocuronium-induced blockade, Sugammadex have been 
shown to be dose-dependent when determining the time until complete reversal.  
In a study by Shields et al. (2006), Sugammadex was administered to 30 patients 
ranked ASA I to III at different doses ranging between 0.5 – 6.0 mg/kg after 2 
hours or greater following the delivery of low dose Rocuronium.  Sugammadex 
effectively reversed each patient within 2 minutes.  Another study showed a 
similar mean time of reversal.  Pavlin and colleagues exhibited a mean reversal 
time of 1.9 minutes when administering Sugammadex to 87 ASA I-III patients, 
and they were able to achieve full reversal after 15 minutes of low dose delivery 
of Rocuronium by using a Sugammadex dose of 4.0 mg/kg (Pavlin, White, 
Viegas, Minkowitz, & Hudson, 2007). 
Sugammadex reversal of a profound blockade by high dosage of 
Rocuronium was also studied.  In a phase II trial conducted at multiple 
international centers, Sugammadex was delivered either 3 or 15 minutes after a 
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Rocuronium dose of either 1.0 or 1.2 mg/kg in 176 ASA I-III patients.  With a 
Sugammadex dose of 8.0 mg/kg, the average time of full reversal was under 3 
minutes for both doses of Rocuronium and at both times after Rocuronium 
administration (Khuenl-Brady, Rex Sielenkamper, & Puhringer, 2005).  These 
trials conclude that Sugammadex was able to completely reverse both shallow 
and profound Rocuronium-induced blockades in a rapid, dose-dependent 
manner. 
Two notable comparative studies performed by the FDA also confirmed 
the ability of Sugammadex to reverse both shallow and profound blockade.  Trial 
19.4.301 sponsored by Schering-Plough in 2005 aimed to reverse shallow 
Rocuronium or Vecuronium induced neuromuscular blockade with a 2.0 mg/kg 
dose of Sugammadex compared to the traditional 50 mcg/kg of Neostigmine.  
Trial 19.4.302 aimed to reverse profound blockade by Rocuronium or 
Vecuronium with a 4.0 mg/kg dose of Sugammadex compared to the 70 mcg/kg 
of Neostigmine.  Sugammadex achieved full reversal at significantly faster times 
than Neostigmine in both trials with no events of residual paralysis or 
reoccurrence of blockade during recovery in PACU.  In Trial 19.4.301, patients 
fully recovered from Vecuronium – induced neuromuscular blockade in 1.4 
minutes with Sugammadex, but full recovery from after Neostigmine 
administration required 17.6 minutes.  Similarly, patients fully recovered from 
Vecuronium – induced blockade in 2.1 minutes with Sugammadex, as opposed 
to an 18.9 minute recovery time with Neostigmine.  In Trial 19.4.302, 
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Sugammadex reversed profound blockade from Rocuronium and Vecuronium in 
2.7 and 3.3 minutes, respectively.  Neostigmine, on the other hand, required 
roughly 50 minutes for full recovery in both two groups (Boer, et al., 2007). 
 Following the publications of these studies, additional studies further 
explored the effectiveness of Sugammadex’s ability of immediate reversal of 
profound blockades following Rocuronium administration.  Groudine and 
colleagues conducted a study to measure the recovery times in 98 male adults 
when using 8.0 mg/kg doses of Sugammadex at either 3, 5, or 15 minutes after 
Rocuronium was administered.  The mean recovery times were 1.8 minutes, 1.5 
minutes, and 1.4 minutes, respectively, and they concluded the reversal was safe 
and well tolerated (Groudine, Soto, Lien, Drover, & Roberts, 2007).  A similar 
study by Sparr and his colleagues measured the recovery times of Sugammadex 
when the dose administered was dependent on the level of blockade measured 
by the nerve stimulator.  A Sugammadex dose ranging from 2.0 – 16 mg/kg was 
administered either after 3 or 15 minutes of administering Rocuronium at 1.0 - 
1.2 mg/kg.  Results show that doses of 2 – 16 mg/kg of Sugammadex 
successfully reversed all neuromuscular blockades.  Furthermore, higher doses 
of Sugammadex showed to reverse at faster times.  Administering Sugammadex 
at doses of 12 – 16 mg/kg reversed profound blockades in 90% of the patients 
within 3 minutes (Sparr, et al., 2007).  These studies conclude that not only does 
higher doses of Sugammadex reverse faster, higher doses are required in order 
to reverse deeper levels of blockade.  This was confirmed in instances where 
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insufficient dosages of Sugammadex resulted in recurarization, which is the 
reoccurrence of the muscle relaxant due to insufficient reversal.   
 Several studies have reported recurarization in their studies where a low 
dose of Sugammadex was used.  A 48 year old ASA - II female weighing 108 kg 
was given 0.5 mg/kg of Sugammadex 42 minutes after a 0.9 mg/kg dose of 
Rocuronium was given.  The nerve stimulator showed a Post-tetanic count of 1, 
which indicated a profound blockade.  Within minutes of administering 
Sugammadex, the blockade deepened indicated by a TOF ratio of 0.25 on the 
nerve stimulator, but the reversal gradually improved to a TOF ratio of 0.9 over 
the next 65 minutes (Eleveld, Kuizenga, Proost, & Wierda, 2007).  Other studies 
using low doses ranging from 0.5 – 1.0 mg/kg of Sugammadex have also 
reported events of insufficient dosage.  Minutes after administering 
Sugammadex, reversal was initially achieved with a TOF ratio of 0.9, but was 
followed by a subsequent decrease in the TOF ratio to under 0.8, indicating an 
inadequate reversal (Suy, et al., 2007; Groudine, et al., 2007). 
 According to Eleveld and colleagues (2007), this recurarization from an 
insufficient dose of Sugammadex may have been due to the redistribution of 
Rocuronium between the central plasma compartment, peripheral compartments, 
and nicotinic junction.  The initial dose of Sugammadex binds plasma 
Rocuronium, drastically decreases the amount of unbound Rocuronium causing 
a return of motor function, and establishes a gradient between central and 
peripheral compartments.  The low concentration of unbound Rocuronium in the 
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central compartment then pulls the unbound Rocuronium from the peripheral 
compartments into the plasma.  Due to an insufficient dose of Sugammadex, 
there is not enough to bind all of the additional Rocuronium molecules, which 
results in Rocuronium re-equilibrating with the nicotinic junctions, also known as 
the effect compartment.  Eleveld reminds us that the correct dose of 
Sugammadex is when it encapsulates all neuromuscular blocking molecules in a 
1:1 ratio, and the use of a neuromuscular monitoring is advised to assure 
adequate reversal (Eleveld, et al., 2007). 
 At the other extreme, there has been one report in a study, where 
Sugammadex was accidentally given at a dose 10 times over the desired dose of 
4 mg/kg.  Although this error was immediately known, the patient was carefully 
monitored and the data collection continued.  The surgery was uneventful, and 
adequate reversal with a TOF ratio of 0.9 was achieved in 1.3 minutes without 
any adverse effects as determined by a blinded safety assessor in the PACU and 
at a 7 day follow-up (Molina, de Boer, Klimekl, Heerina, & Klein, 2007).   
Comparison to Cholinesterase Inhibitor Reversal 
 There have been multiple comparative studies during stage III clinical 
trials to the current standards of anesthesia.  Before Sugammadex, the 
cholinesterase inhibitors, Neostigmine and Edrophonium, were the standards for 
reversal of neuromuscular relaxing agents.  A study by Blobner and colleagues 
compared the effectiveness of Sugammadex to Neostigmine in the reversal of 
shallow blockades by Rocuronium.  Ninety eight ASA Class I – III patients over 
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the age of 18 were randomized to receive either 2.0 mg/kg of Sugammadex or 50 
mcg/kg of Neostigmine along with 10 mcg/kg of Glycopyrrolate.  Sugammadex 
and Neostigmine were both administered at conventional times in the surgery, 
near the end of the operation after two of the four muscle twitches were observed 
with the nerve stimulator.  The median times to full reversal for Sugammadex and 
Neostigmine were 1.4 minutes and 17.6 minutes, respectively.  With no residual 
paralysis or re-curarization observed, Sugammadex showed to safely provide 
significantly faster reversals of shallow Rocuronium induced muscle blockades 
compared to Neostigmine (Blobner, et al., 2007) 
 Similar studies were performed by Sacan and Flockton in 2007.  Sacan 
and colleagues randomized sixty ASA Class I – III patients to receive either 
Sugammadex, Neostigmine or Edrophonium in patients with moderately 
profound neuromuscular blockade from Rocuronium.  While Sacan does not 
clearly describe a moderately profound state, the reversal agents were 
administered after observing one of the four twitches with the nerve stimulator.  
This is also the earliest time that Neostigmine and Edrophonium can be 
administered, as only Sugammadex is capable of reversal when no twitches are 
observed.  A Sugammadex dose for moderate muscle blockade, 4.0 mg/kg, was 
used and compared with standard dose ranges of Neostigmine (70 mcg/kg), 
Glycopyrrolate (14 mcg/kg), Edrophonium (1 mg/kg), and Atropine (10 mcg/kg).  
The mean time of full reversal and recovery for Sugammadex, Neostigmine, and 
Edrophonium were 1.78 minutes, 17.44 minutes, and 5.52 minutes, respectively 
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(Sacan, et al., 2007).  Sugammadex was shown to significantly achieve faster 
reversal of Rocuronium induced muscle blockades compared to both 
Neostigmine and Edrophonium.  Comparatively, Flockton achieved similar results 
favoring Sugammadex.  In his study, reversing profound Rocuronium induced 
muscle blockade with Sugammadex 4.0 mg/kg was compared with using 
Neostigmine 70 mcg/kg and Glycopyrrolate 14 mcg/kg.  The mean times of 
recovery for Sugammadex and Neostigmine were 2.9 minutes and 50.4 minutes, 
respectively (Flockton, 2008).   
 Other comparative studies began using various neuromuscular relaxing 
agents other than Rocuronium.  Lemmens and colleagues compared the 
recovery times of Sugammadex on shallow Rocuronium blockade with the 
recovery times of Neostigmine on shallow Cis-Atracurium blockade.  Cis-
Atracurium is a non-depolarizing neuromuscular blocking agent similar to 
Rocuronium, but it has the shortest acting profile of all in this category.  Eighty 
four ASA Class – I – III adult patients were randomized to receive either 
Rocuronium or Cis-Atracurium for muscle paralysis.  After muscle paralysis was 
not needed, the patients received either Sugammadex or Neostigmine after two 
twitches out of four were observed with the nerve stimulator.  The mean times for 
full reversal by Sugammadex and Neostigmine were 1.9 minutes and 9.0 
minutes, respectively (Lemmens, et al., 2007).  Although recovery with Cis-
Atracurium by Neostigmine was faster than studies with Rocuronium, as 
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expected, Sugammadex still showed to be significantly faster in achieving full 
reversal.   
 The final two comparative studies involved comparing Sugammadex and 
Neostigmine on the reversal of shallow and profound blockade from Vecuronium, 
yet another non-depolarizing neuromuscular blocking agent.  Its duration of 
action falls between Rocuronium and Cis-Atracurium, and it is able to be 
reversed by Sugammadex but at a lower efficiency than Rocuronium.  Reversal 
of shallow Vecuronium blockade was studied by Alvarez-Gomez.  His study 
concluded that Sugammadex achieved significantly faster full reversal than 
Neostigmine with mean times of 2.1 minutes and 18.9 minutes, respectively 
(Alvarez-Gomez, 2007).  In another study Jones and colleagues recorded the full 
reversal times of eighty three ASA Class I – III adult patients randomized to 
receive either Sugammadex or Neostigmine for the reversal of profound 
Vecuronium induced blockade.  The mean times to full reversal for Sugammadex 
and Neostigmine were 4.5 minutes and 66.2 minutes, respectively (Jones, et al., 
2007) 
 There are two things that can be drawn from these comparative studies of 
Sugammadex to Neostigmine.  Sugammadex has shown to be significantly faster 
at fully reversing the paralyzed patient despite which muscle relaxant or 
conventional cholinesterase inhibitor was used for comparison (p<0.000).  With 
no residual paralysis or re-curarization, it can be concluded that Sugammadex is 
both a safe and more effective alternative.  When observing the range of reversal 
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times for mean calculation, Neostigmine showed to have a much larger range 
compared to Sugammadex.  In Lemmens’ study (2007), recovery times for 
Neostigmine ranged from 4.2 to 28.2 minutes, while Sugammadex ranged from 
0.7 to 6.4 minutes.  In Blobner’s study (2007), Neostigmine ranged from 3.7 to 
106.9 minutes, while Sugammadex ranged from 0.9 to 5.4 minutes.  In Sacan’s 
study (2007), the mean recovery time for Neostigmine was 17.44 (± 9.8) minutes, 
while mean recovery time for Sugammadex was 1.78 (± 1.1) minutes.  This 
shows that from person to person, Sugammadex is more consistent in its 
encapsulation mechanism of action, while the wide range for Neostigmine 
reflects how its competitive antagonism mechanism of action variably affects 
each individual. 
Comparison to Succinylcholine Recovery 
 The immediate reversal of Rocuronium with Sugammadex had made it the 
subject for comparison with Succinylcholine in multiple studies.  As previously 
mentioned, Succinylcholine has the shortest duration of action of all the NMBAs 
currently available.  At a dose of 1 mg/kg, it achieves complete neuromuscular 
blockade in 1 minute, and it achieves adequate return of motor functions with a 
TOF ratio of 0.9 in 10 – 13 minutes.  Three studies will be presented to show the 
recovery times of Rocuronium and Sugammadex compared to Succinylcholine in 
general elective surgery, surgeries requiring rapid sequence induction, and in 
electro convulsive therapy. 
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 In a study by Lee and colleagues (2009), One hundred and fifteen ASA 
Class I – II patients between the ages of 18 and 65 received either 1.0 mg/kg of 
Succinylcholine or 1.2 mg/kg of Rocuronium and 16 mg/kg of Sugammadex for 
neuromuscular relaxation in their elective surgical procedures.  Sugammadex 
was administered 3 minutes after Rocuronium administration, and the 
spontaneous muscle recovery times of each blinded patient groups were 
recorded.  The mean times of recovery to a TOF ratio of 0.1 and 0.9 for patients 
given Succinylcholine were 7.1 and 10.9 minutes, respectively.  Meanwhile, the 
mean times of patients given Sugammadex were 4.4 and 6.2 minutes, 
respectively.  Sugammadex was shown to provide significantly faster recovery 
times compared to Succinylcholine (Lee, 2007).  Lee further concluded that since 
Rocuronium is currently indicated in roughly 25% of cases requiring rapid 
sequence induction, Sugammadex would be more effective in achieving 
immediate restoration of muscle functions. 
 As previously described, rapid sequence induction of a patient is an 
anesthetic technique to quickly intubate the patient after unconsciously sedating 
them.  This is often used in the pregnant patient, patients with increased risk of 
pulmonary aspiration of gastric contents, and in the emergency setting where we 
cannot confirm if a patient undergoing surgery has an empty or full stomach.  
Succinylcholine is currently the standard for this procedure since if the event of 
an unanticipated difficult airway arises, the patient will be able to recover from 
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muscle relaxation and breathe spontaneously shortly after Succinylcholine 
administration.  
 In a study by Sorensen and colleagues, 61 patients undergoing general 
elective surgery that required rapid sequence induction were randomized to 
either receive 1 mg/kg of Succinylcholine or 1 mg/kg of Rocuronium with 16 
mg/kg of Sugammadex immediately given upon verification of proper placement 
of the endotracheal tube.  The time of full recovery and patient’s return to 
breathing spontaneously was recorded for both groups.  The median time from 
tracheal intubation to spontaneous ventilation was 6.8 minutes for patients 
receiving Succinylcholine, and the median time was 3.6 minutes for patients 
receiving Rocuronium and Sugammadex.  Sorensen concluded that patients 
receiving Sugammadex resulted in a significantly earlier re-establishment of 
spontaneous ventilation than patients with Succinylcholine (Sorensen, 2012).  
While the recovery time to a TOF ratio of 0.9 was also recorded, it is noteworthy 
to emphasize the recovery time of spontaneous ventilation because it is more 
clinically important especially in this scenario. 
 The final comparative study with Succinylcholine is a case report of a 69 
year old woman undergoing electro convulsive therapy.  Ever since the 
introduction of this procedure in the 1950s, Succhinylcholine has remained as the 
most common neuromuscular relaxing agent used for temporary paralysis 
required by this short procedure.  However, studies have shown Succinylcholine 
to be unsafe in patients susceptible to malignant hypothermia and neuroleptic 
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malignant syndrome.  In this case report, Succinylcholine was contra-indicated 
due to a patient history of neuroleptic malignant syndrome, Parkinson’s disease, 
rheumatoid arthritis, celiac disease, and hypertension.  Ramamoorthy and 
colleagues administered 1 mg/kg of Rocuronium and 16 mg/kg of Sugammadex 
5 minutes afterwards.  Muscle relaxation with Rocuronium achieved the 
prevention of violent muscle contractions during the shock therapy, and recovery 
times for TOF ratio to 0.9 and recovery time to spontaneous breathing were 2 
minutes and 3 minutes, respectively.  The patient was stable throughout the 
procedure, and Sugammadex was concluded to be both an effective and safe 
alternative when Succinylcholine is contra-indicated in the patient 
(Ramamoorthy, 2011). 
Trials on Patient Specific Populations 
 All Phase III clinical studies presented up until now have had similar 
exclusion criteria, specifically the exclusion of age extremes, pregnancy, and 
patient history of heart disease, lung disease, renal disease, or neuromuscular 
disorders.  The following Phase III clinical trials study the effectiveness of 
Sugammadex on these various patient populations, as well as recording possible 
alterations in outcome due to changes in normal physiology. 
Pediatric 
 Pediatric patients differ from adult patients in many ways physiologically, 
and this affects the pharmacokinetics and pharmacodynamics of drugs.  
Rocuronium, for example, has shown to have a greater potency and shorter 
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duration in infants and children than in adults.  Residual paralysis has also shown 
to occur more frequently in children than adults (Plaud, 2009).  The first study of 
Sugammadex on infants, children, and adolescents compared to adults was 
performed by Plaud and his colleagues in 2009.  His aim was to simply 
determine the dose – response relationship of Sugammadex, as well as its 
safety.   
Eight infants, 24 children, and 31 adolescents were given Propofol for 
induction and either opioids or regional anesthesia for analgesia.  Rocuronium at 
a dose of 0.6 mg/kg was given to all patients, and either Sugammadex or a 
placebo was given when two out of four twitches were observed by the nerve 
stimulator.  The dose of Sugammadex or placebo varied from 0.5 – 4.0 mg/kg in 
each age group.  The time until full recovery, defined by a TOF ratio of 0.9, was 
recorded, while documenting any signs of inadequate reversal (TOF < 0.9) or 
reoccurrence of the blockade, defined as a TOF ratio declining from 0.9 to 0.8 
and below.  Other safety assessments were employed by use of 
electrocardiography, laboratory values, and notation of adverse events. 
 The time from Rocuronium administration to appearance of two of four 
twitches was shorter for infants, adolescents, and children than for adults, as 
expected, with their median times being 28.0, 20.5, 25.3, and 32.4 minutes, 
respectively.  The median times to full recovery after Sugammadex were 0.6 – 
3.7 minutes in infants, 0.6 – 3.7 minutes in children, 1.1 – 4.6 minutes in 
adolescents, and 1.2 – 4.2 minutes in adults.  This range is dose-dependent with 
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shorter times associating with a high Sugammadex dose of 4.0 mg/kg, and 
longer times associating with a low dose of 0.5 mg/kg.  The placebo group had a 
median recovery time of 21.0, 19.0, 23.4, and 28.5 minutes in infants, children, 
adolescents, and adults, respectively.  Plaud’s findings were consistent with 
previous phase II studies, that a dose of 2.0 mg/kg or greater would reverse the 
patient in a median time of less than 2 minutes.  The authors concluded that 
Sugammadex overall was effective and well tolerated in each pediatric age 
group.  Since it is much harder to recruits pediatric patients to studies, no firm 
conclusions can be drawn on its safety due to their small sample sizes (Plaud, et 
al., 2009). 
Geriatric 
 Similar to the pediatric patient, a drug’s efficacy and metabolism may all 
become altered in an elderly patient.  Changes in their receptor sensitivity, 
impairment of physiological functions in organs, and presence of chronic 
diseases all affect the pharmacokinetics and pharmacodynamics of drugs.  
Several neuromuscular blocking agents including Rocuronium, for example, all 
have an increased time of onset and increased duration of action in the elderly.  
An increased time of onset may be due to decreased cardiac functions resulting 
in longer times for a drug to reach their effector site.  An increased duration of 
action may be due to decreased ability to metabolize and excrete the drug, 
characteristics of an impaired liver or kidney that often accompanies aging. 
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 The first study on the elderly population was performed by McDonagh and 
colleagues (2007).  They explored the efficacy and safety of Sugammadex on 
150 patients.  Forty eight adults (age 48 – 64 years), Sixty two elderly (age 65 – 
74 years), and forty old elderly (age >75 years) all received 2.0 mg/kg 
Sugammadex after observing two of four twitches following the administration of 
0.6 mg/kg Rocuronium.  The mean time to full recovery in the adult, elderly, and 
old elderly groups was 2.3, 2.6, and 3.6 minutes, respectively (McDonagh, et al., 
2007).   
McDonagh concluded the adult group had a significantly faster recovery 
time compared to the two elderly groups.  Factors contributing to this, as 
previously stated, are slow cardiovascular circulation, altered receptor expression 
at the neuromuscular junction, and also altered perfusion of Rocuronium 
between compartments.  Despite a slower recovery, the times obtained were still 
significantly faster to studies comparing Sugammadex 2.0 mg/kg with 
Neostigmine 50 mcg/kg (Jones, et al., 2007).  Since Neostigmine has shown in a 
past study to have decreased potency in reversal of blockades in patients older 
than 70 years compared to adults, Sugammadex proves to be an effective and 
well tolerated alternative. 
Cardiac 
 A study on 121 cardiac patients was conducted by Dahl and colleagues 
(2007).  These cardiac patients were between ages of 36 – 90 years, ranked 
ASA Class II – IV, and underwent non-cardiac surgery using Rocuronium 
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induced blockade.  Sugammadex 2.0 mg/kg, 4.0 mg/kg, or a placebo was given 
after two of four twitches, and the time to full recovery was recorded along with 
any adverse events by means of vigilant electrocardiograph monitoring.  The 
mean recovery time for groups receiving 2.0 mg/kg, 4.0 mg/kg, and placebo was 
1.7, 1.4, and 34.4 minutes, respectively.  While Sugammadex proved to safely 
and effectively reverse the blockade, two patient cases involved episodes of QTc 
interval prolongation, one in the Sugammadex group and one in the placebo 
group (Dahl, et al., 2007).  The inhalational anesthetics, used for the prolonged 
induction of the patient throughout the case, were not disclosed.  Inhalational 
anesthetics have shown in past studies to cause QTc prolongation (Schmeling, 
et al., 1991; Kleinsasser, et al., 2000).  However, there had also been studies 
previously stating possible association of Sugammadex with QTc prolongations 
(Gijsenbergh, et al., 2005; Vanacker, et al., 2006; Sorgenfei et al., 2006). 
  Due to potentially finding a possible adverse effect of Sugammadex, de 
Kam and his colleagues (2007) performed a study on 62 volunteers by 
eliminating all agents that may prolong QTc intervals, while evaluating only 
Sugammadex and comparing the drug to Moxifloxacin, a known drug to cause 
QTc prolongation.  The 62 volunteers were randomized to receive either 4.0 
mg/kg or 32 mg/kg Sugammadex with or without Rocuronium or Vecuronium, 
400 mg of Moxifloxacin, or placebo.  No significant QTc prolongation was 
observed with the placebo and Sugammadex with or without co-administration of 
Rocuronium or Vecuronium.  Significant QTc prolongation with Moxifloxacin was 
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observed as expected.  De Kam concluded that previous studies with 
Sugammadex resulting in QTc interval prolongations are most likely due to other 
agents used or due to cardiac diseases, particularly defects in conduction (Kam, 
et al., 2007). 
Pulmonary 
 Effects and safety of Sugammadex were studied on patients with history 
of pulmonary disease by Amao and colleagues in 2007.  Seventy-seven adult 
patients undergoing general surgery (ASA class II – III), all with known history or 
recently diagnosed with pulmonary disease, were given Rocuronium 0.6 mg/kg 
and Sugammadex 2.0 mg/kg or 4.0 mg/kg after two of four twitches were 
observed.  As expected, the mean recovery time to a TOF ratio of 0.9 for both 
the group that received 2.0 mg/kg and 4.0 mg/kg was 2.1 and 1.8 minutes, 
respectively.  Regarding the safety of Sugammadex on pulmonary patients, 
Amao concluded that Sugammadex was well tolerated and effective in its 
reversal of blockade with no alterations in respiratory rate or incidence of 
recurarization in any of the patients (Amao, et al., 2007). 
There were, however, two incidences of serious bronchospasm episodes 
in two patients who had a history of asthma. Since patients with asthma or other 
pre-existing lung diseases are highly susceptible to pulmonary complications 
during intubation and extubation, bronchospasms being most common, it cannot 
be concluded that Sugammadex was the sole cause of these incidences.  Amao 
noted that while one patient suffered from bronchospasm following extubation, 
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the other patient had a bronchospasm episode before extubation and 55 minutes 
after receiving Sugammadex.  While this suggests possible connection with 
Sugammadex, Amao also states that Desflurane was the inhalation agent used 
in each of these two cases.  Desflurane, unlike Sevoflurane or Nitrous Oxide, is a 
noxious agent that is known to irritate the airway.  Amao advises physicians to be 
prepared for bronchospasms in patients with underlying lung disease even 
though Sugammadex was shown to be effective and well tolerated (Amao, et al., 
2007). 
The effects of Sugammadex on bronchial smooth muscles, the muscles 
involved in bronchospasm, were later studied by Yoshioka and colleagues in 
2012 in order to determine from Amao’s study if Sugammadex was involved in 
the cases where bronchospasm had occurred.  The left main bronchus was 
extracted from male Wistar rats by thoracotomy under anesthesia.  Through 
measuring of the isometric contraction of the circular smooth muscle of the 
bronchus, the baseline tension and ACH induced contraction were examined 
before and after the tissues were bathed in a solution containing Sugammadex 
sodium.  Yoshioka’s results showed that Sugammadex did not induce bronchia 
smooth muscle contraction since there were no changes to the baseline tension 
when administered.  Furthermore, its effects did not augment or dampen the 
bronchial smooth muscle contraction response when induced with ACh 
(Yoshioka, et al., 2012). 
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However, there are three possibilities that require further study.  First, the 
rats used were healthy, while the patients in Amao’s study were asthmatic.  It is 
unknown whether Sugammadex has an effect when the bronchial smooth 
muscles are hyperresponsive, as with asthmatic patients.  Secondly, while 
Sugammadex itself did not cause any contractions in the rats, it is possible that 
the Sugammadex-Rocuronium chelated complex may have triggered a response.  
Since Rocuronium was not involved in this study, this possibility was not 
explored.  Lastly, alternate factors that lead to in vivo bronchospasm such as 
cholinergic nerve stimulation and mast cell activation were not explored.  It is still 
possible that Sugammadex or its complex with Rocuronium is involved in 
augmenting these pathways. 
Renal Insufficiency 
 Patients with renal insufficiency and end stage renal disease experience 
longer durations from drugs.  This is due to the fact that while the liver 
metabolizes the drug, its metabolites may still have an active effect depending on 
the drug (Staals, et al., 2008).  Therefore, its effects are not truly ceased until the 
active metabolite is excreted by the kidney.  While some neuromuscular blocking 
agents like Cisatracurium are eliminated in the plasma by Hoffman degradation, 
other neuromuscular blocking agents such as Rocuronium and Pancuronium are 
excreted by the kidney.  Therefore, prolonged blockades are often reported in 
patients with renal failure (Craig, et al., 2008, Cammu, et al., 2012).   
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 Since Sugammadex and its complex with Rocuronium are also cleared by 
the kidneys, Staals and his colleagues studies its safety and efficacy in patients 
with normal and severe renal diseases.  54 patients with normal renal function 
and 61 patients with impaired renal function, characterized by a creatinine 
clearance under 30 mL/minute, were given Propofol for induction, opioids for 
analgesia, Rocuronium 0.6 mg/kg for muscle paralysis, and Sugammadex for 
reversal after two of four twitches were observed.  Times to full recovery with a 
TOF ratio of 0.9 were recorded, and possible adverse events were assessed.
 Analysis of the plasma concentration was also conducted to assess the 
pharmacokinetics of Sugammadex and Rocuronium in patients with end stage 
renal failure.  Plasma concentrations of Sugammadex in these patients revealed 
that its clearance was 17 times slower than patients with normal renal function, 
and its terminal half-life increased by 16 fold.  Furthermore, due to their abnormal 
physiology, their volume of distribution was greater by 20%, which ultimately 
means Sugammadex exposure was prolonged by 16 fold.  Its complex with 
Rocuronium also remained in the plasma for a longer time period.  Regardless of 
this data, the mean time to full recovery for patients with normal renal function 
and patients with impaired renal function was 1.7 and 2.0 minutes, respectively.  
Staals concluded that although patients with normal renal function had a 
significantly faster time of recovery, Sugammadex still provided safe and 
effective reversal of Rocuronium induced blockade in both these patient groups 
with no events of recurarization (Staals, et al., 2007). 
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Liver Dysfunction 
 Neuromuscular blocking agents such as Rocuronium are known to have a 
prolonged effect in patients with impaired liver function.  While Rocuronium is 
excreted by the kidney as previously stated, its primary method of elimination is 
through the liver by carrier-mediated transport and cytochrome P450 mediated 
metabolism, specifically the CYP3A4 enzyme (Craig, et al., 2008).  While there 
has not been any animal studies or clinical trials on patients with liver disease, 
data from Schering-Plough’s simulation in hepatic impairment suggest that a 
Sugammadex dose of 2.0 mg/kg and 4.0 mg/kg given when two of four twitches 
are observed would result in a 2.55 minutes and 4.12 minutes longer recovery 
time, respectively, compared to patients with normal liver function.  A dose of 16 
mg/kg showed little difference between normal and impaired liver function (Craig, 
et al., 2009).  These results show that time to full recovery with Sugammadex is 
still faster than using Neostigmine. 
 In 2012, two case reports by Carron and Batistaki were published 
regarding the safety and effectiveness of Sugammadex as an alternative to 
Neostigmine in patients with liver diseases.  The first case report, published by 
Batistaki and colleagues, documents the effects of Sugammadex on three ASA 
Class III patients with liver dysfunction undergoing transjugular intrahepatic 
portosystem shunts.  Two of the patients had Budd-Chiari syndrome, and the 
third patient had hepatitis C induced liver cirrhosis.  2.0 mg/kg Sugammadex was 
given, when four twitches were observed, to reverse Rocuronium administered at 
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1.0 - 1.2 mg/kg.  The time from administering Sugammadex until a TOF ratio of 
0.9 ranged from 98 – 540 seconds among the three patients.  Adverse effects 
and recurarization were not observed (Batistaki, et al., 2012).  These results 
were consistent with Schering-Plough’s simulated pharmacodynamics model, 
suggesting that a 2.0 mg/kg dose of Sugammadex would result in a 2.55 minute 
longer reversal time compared to a reversal time of 2.8 minutes in patients with 
normal liver function (Batistaki, et al., 2012). 
The second case report was published by Carron and colleagues (2012).  
Carron opted to use Sugammadex in a morbidly obese patient diagnosed with 
non-alcoholic steatohepatitis undergoing a laparoscopic sleeve gastrectomy.  
Due to a potential difficult airway, risks of aspiration, and underlying liver disease, 
Carron was concerned that Neostigmine would fail to fully reverse the 
Rocuronium induced blockade within 10 minutes.  After an uneventful procedure 
lasting 60 minutes, there was still no twitch observed by the nerve stimulator.  
Rocuronium’s effect was drastically prolonged, and two of four twitches were not 
observed until 120 minutes after the intubating dose of Rocuronium was 
administered (a single bolus of 0.6 mg/kg).  Neostigmine at 70 mcg/kg and 
Atropine at 15 mcg/kg were given to reverse the blockade, but the TOF ratio was 
still only 0.18 after 30 minutes.  Sugammadex was ultimately decided upon.  Four 
minutes after a dose of 2.0 mg/kg.  The TOF ratio increased from 0.18 to 1.0.  
The author concluded that Sugammadex was advantageous over Neostigmine in 
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morbidly obese patients with liver disease due to effective and timely reversal 
(Carron, et al., 2012). 
Neuromuscular Disorder 
 Neuromuscular disorders increase the risk of perioperative respiratory and 
cardiovascular complications due to underlying pathology that lead to muscle 
weakness, pulmonary insufficiency, and progressive paralysis.  When treated 
with a neuromuscular blocking agent, recurarization and residual paralysis is a 
major concern in the post-operative period.  In the past 2 years, two case reports 
and one clinical study have published the effects of Sugammadex on patients 
with myotonic dystrophy, spinal muscular atrophy, and myasthenia gravis.   
 Stewart and colleagues published a case report in 2012 on two patients 
receiving Sugammadex for reversal of Rocuronium induced blockade.  Both 
patients required a rapid intubation to protect the airway due to possible 
complications from their neuromuscular disorder.  Rocuronium and Sugammadex 
were used due to the fact that Succinylcholine was contra-indicated in these 
patients.  The first patient was diagnosed with myotonic dystrophy upon arrival 
for elective surgery.  Sugammadex at 2.7 mg/kg was given to reverse 
Rocuronium induced blockade upon observing two of four twitches.  Time of 
recovery to a TOF ratio of 0.9 was 5 minutes, and no signs of recurarization was 
observed afterwards (Stewart, et al., 2012).   
 The second patient was diagnosed with spinal muscular atrophy and 
consequent COPD.  Sugammadex at 4.0 mg/kg was given 17 minutes after 
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Rocuronium administration, where no twitches were observed.  The recovery 
time of this profound blockade was 2.8 minutes, and no signs of recurarization or 
residual paralysis were observed afterwards.  The author concluded that reversal 
of Rocuronium by Sugammadex was safe, rapid, and without recurarization 
(Stewart, et al., 2012). 
 The second case report documents Pickard and colleagues as they 
administer Rocuronium and Sugammadex to a 14 month old boy with myotonic 
dystrophy scheduled for multiple surgeries requiring muscle relaxation.  
Succinylcholine and Neostigmine are both contra-indicated in this case.  
Succinylcholine provokes generalized myotonic contractures, resulting in a 
difficult time providing positive pressure ventilation if the chest wall muscles 
become rigid.  Neostigmine and other anticholinesterases have a potential to 
trigger myotonic episodes, as well as worsening a neuromuscular block.   
These agents were avoided, and Sugammadex at 5mg/kg was given to 
reverse profound Rocuronium blockade, characterized by the absence of any 
twitches even after 57 minutes of Rocuronium administration.  After 26 seconds, 
TOF ratio was 0.96, but over the next few minutes the ratio had fallen to 0.6.  
Sugammadex at a dose of 5 mg/kg was re-administered, and after 13 seconds 
the TOF ratio remained stable at 0.86.  The author concluded that an insufficient 
dose was given initially resulting in recurarization, but overall Sugammadex was 
advantageous in this scenario where a fast and safe agent was needed to 
reverse a profound block (Pickard, et al., 2013).   
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   The final publication is by Sungur Ulke and colleagues (2013), 
documenting the use of Sugammadex in ten patients with myasthenia gravis 
undergoing thymectomy.  As with all neuromuscular disorders, the 
anesthesiologist is challenged with the question of using or not using 
neuromuscular blockers and anticholinergics, as well as the appropriate dosage 
if used.  Therefore, even though the use of Rocuronium is controversial, the 
study aimed to evaluate if Sugammadex was useful in treatment approaches 
involving Rocuronium.  The ten patients were given 2.0 mg/kg Sugammadex, 
and carefully monitored to require re-dosing or not.  The initial dose of 2.0 mg/kg 
of Sugammadex was enough to sufficiently reverse all ten patients, with a mean 
time to full reversal ranging from 35 to 240 seconds.  None of the patient needed 
assisted mechanical ventilation due to respiratory failure or myasthenic crisis.  
The author concluded that Rocuronium and Sugammadex is a safe and effective 
alternative for myasthenic patients who require muscle paralysis during surgery 
(Ulke, et al., 2013). 
Adverse Effects 
 There have only been a few adverse effects that have been documented 
during the clinical trial phase.  While no one were serious adverse effects, they 
included: hypotension, coughing, movement, nausea, vomiting, dry mouth, 
abnormal taste and smell, sensation of changed temperature, erythema, 
tachycardia, bradycardia, pyrexia, abnormal n-acetyl-glucosaminidase levels in 
the urine, and QT interval prolongation (Gijsenbergh, et al., 2005; Sorgenfrei, et 
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al., 2006; Shields, et al., 2006; Dahl, et al., 2007).  As previously discussed, a 
study later showed that Sugammadex doses up to 32 mg/kg was not the cause 
of QT interval prolongation (de Kam, et al., 2007).  Even in one study where over 
dosage occurred by administration of 40 mg/kg rather than 4 mg/kg, effective 
reversal of Rocuronium was noted without any adverse effects. 
 However, the Food and Drug Administration have reviewed the 
documented adverse effects, and were concerned that as a whole, these effects 
represented anaphylactic/anaphylactoid reactions.  This resulted in a letter 
issued to Schering-Plough Pharmaceutical in July of 2008 stating their un-
approval.  While clinical studies resumed the addressing of this issue, it is 
noteworthy to mention that ever since the European regulatory commission 
approved Sugammadex for use in August 2008, no adverse outcomes have been 
published since its incorporation in clinical practice. 
Discussion 
Clinical Assessment 
 Results collected from these randomized trials indicate that Sugammadex 
is more effective than Neostigmine for reversal of neuromuscular blockade.  This 
was indicated by monitoring the TOF ratio and comparing the time needed to 
reach full reversal.  Patients reversed with Sugammadex had a narrower range of 
recovery times, making its time of effect more predictable than Neostigmine.  
Results from other trials have shown Sugammadex to be both safe and effective 
in reversal of moderate to profound neuromuscular blockades induced by 
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Rocuronium or Vecuronium.  This ability is dose-dependent and unique to 
Sugammadex.   
These three characteristics of Sugammadex allow the anesthetist to 
continue a neuromuscular blockade of any level in a patient up until the time of a 
surgical conclusion without the worry of being unable to reverse a patient’s 
neuromuscular blockade.  Surgical procedures that require profound 
neuromuscular blockade throughout the procedure will benefit from 
Sugammadex.  This includes diagnostic imaging, spine surgery, and procedures 
requiring the immobility of the head.  The inability of Neostigmine to reverse 
profound blockade equates to several common clinical obstacles.   
Firstly, profound blockades require extra time after surgical completion in 
order to wait for a blockade to fall to a level adequate for reversal.  To prevent 
these prolongations, anesthetists often taper or discontinue the neuromuscular 
blocking agent towards the end of the procedure.  This allows the blockade to fall 
to an adequate level for reversal around the same time the surgeon is finished, 
but this causes risks of patient movement.  Secondly, a surgeon may request 
deeper levels of muscle paralysis, but the anesthetist would often be reluctant 
due to the increasing difficulty to reverse especially nearing the end of a surgery.
 Lastly, it is possible that a patient may cough on the endotracheal tube or 
exhibit movement of the diaphragm despite careful neuromuscular monitoring of 
the anesthetist.  This is due to the fact that the muscles of the larynx and the 
diaphragm are more resistant to the effects of neuromuscular blocking agents 
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than muscles in the rest of the body (Caldwell, et al., 2009).  If the adductor 
pollicis or orbicularis oculi, two muscles targeted and monitored by the nerve 
stimulator, both appear to show absence of twitch, coughing and attempts of 
spontaneous breathing may still occur.  These clinical situations would cease to 
exist if a larger dose of Rocuronium can be given periodically to achieve constant 
profound blockade without fear of the inability to reverse in a timely manner. 
 Sugammadex administered at 16 mg/kg, 3 minutes following Rocuronium 
administration, has shown to provide faster recovery than the spontaneous 
recovery from Succinylcholine.  While Succinylcholine is the only neuromuscular 
blocking agent that can provide muscle paralysis under 1 minute and recovery 
under 10 minutes, it has undesired effects and it is contraindicated in several 
scenarios previously mentioned.  The safer drug, Rocuronium, in combination 
with Sugammadex provides the alternative that is needed in the medical 
community for procedures requiring short onset and duration of muscle paralysis.  
Cases requiring rapid sequence induction, difficult intubation cases, and 
extremely short procedures all benefit greatly from having a safer alternative to 
Succinylcholine. 
 Trials on specialized groups with coexisting diseases have shown 
effective and safe results from Sugammadex administration.  Sugammadex has 
currently shown no serious adverse effects associated with its administration.  Its 
side effect profile is low compared to the two current reversal agents on the 
market, Neostigmine and Edrophonium.  As discussed, anti-muscarinic agents 
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such as Atropine or Glycopyrrolate are co-administered due to the hemodynamic 
instability associated with these two drugs.  However, studies have shown that 
even with co-administration of anti-muscarinic drugs, Neostigmine can still result 
in severe bradycardia and provoked coronary artery vasospasms in patients with 
autonomic dysfunction (Caldwell, et al., 2009).  Furthermore, anti-muscarinic 
drugs do not always perfectly balance the effects of anticholinesterase reversal 
agents.  This results in cases where heart rate significantly changes with 
conventional reversal protocols (de Kam, et al., 2010).  Some anesthetists, as a 
result, would completely omit the pharmacological reversal of neuromuscular 
blocking agents in cardiac patients in order to avoid an imbalance in oxygen 
supply and demand in the heart.  Since Sugammadex has no effects on heart 
rate and blood pressure, it would greatly benefit patients with coronary artery 
disease or with other compromises in the heart.   
 Patients with acute or chronic pulmonary diseases in obstructive or 
restrictive nature will benefit from Sugammadex due to a faster and more 
effective reversal of muscles associated with breathing and airway.  Inadequate 
reversals may lead to a feeling of shortness of breath or difficulty in breathing.  
Ineffective reversal of pharyngeal muscle tone compromises the airway, which is 
especially detrimental to patients with obesity and obstructive sleep apnea.   
Economic Assessment 
 Sugammadex is purchased by clinical institutions as the brand name 
Bridion, manufactured by Organon/Schering-Plough USA.  Ten vials, each 
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containing 5 mL of 100 mg/mL Sugammadex, costs roughly $2014.04 
(Chambers, 2010).  A single use of Sugammadex at a dose of 4 mg/kg would 
cost roughly $112.79 for a 70kg patient.  For comparison, Neostigmine (1 
mg/mL) is available as a generic, costing $1.99 for a 5 mL vial depending on the 
manufacturer.  A single vial is sufficient for the reversal of a patient.  Due to this 
dramatic price difference, cost-effectiveness studies have been conducted to 
assess whether its high cost is justified by the decreased time in the OR and 
PACU, enabled by the effectiveness of Sugammadex.  This would determine if it 
is feasible to implement Sugammadex for routine use or for special 
circumstances. 
 Paton and colleagues (2010) assessed the cost-effectiveness of 
Sugammadex by studying the outcomes of patients administered with either 
Rocuronium or Vecuronium, and reversed with either Sugammadex or 
Neostigmine with Glycopyrrolate.  The total cost of each case was determined, 
and the length of stay in the OR and in recovery was recorded.  The rates of 
serious adverse effects and the rates of a reoccurring or residual blockade 
between the two anesthetic strategies were calculated.  Since any reduction in 
recovery time by using Sugammadex represents resources saved by the facility, 
the total cost per minute of the staff was determined.  The estimated total staff 
cost associated with the recovery period in a British facility is £4.44 per minute.  
Therefore, if inadequate reversal, recurarization, or serious adverse effects occur 
in the PACU, each additional hour of stay equates to a cost of £19.61 for the 
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institution.  Under these assumptions, Paton assessed the data from comparative 
studies of Sugammadex and Neostigmine.  In studies conducted by Blobner et 
al, and Jones et al, patients with moderate to profound neuromuscular blockade 
showed a 23.37 and 24.24 minute decrease in recovery time when using 
Sugammadex to reverse Rocuronium and Vecuronium, respectively (Paton, et 
al., 2010).  With roughly £106.56 saved, Sugammadex becomes cost-effective in 
this scenario. 
 When assessing the cost and benefit of using Sugammadex over 
Succinylcholine in a rapid sequence induction or difficult airway scenario, 
Sugammadex is assumed to result in a reduced risk of morbidity and mortality.  
The dangers of Succinylcholine and the faster recovery times with Sugammadex 
from the presented literature support this assumption.  While it is unlikely that 
decreasing patient deaths and unfavorable outcomes would result in significant 
savings in cost for an institution, it will be up to each individual institution to 
decide if the safety benefits outweigh its cost. 
Conclusion 
 This study on the necessity, safety, and effectiveness of Sugammadex in 
our current healthcare practices is based on published clinical studies from both 
the clinical trial phase and from its implementation in the United Kingdom.  The 
data suggests that Sugammadex is both a safe and effective agent for the 
reversal of Rocuronium and Vecuronium induced neuromuscular blockade.  
There appears to be no serious adverse effects associated with its use, unlike 
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drugs such as cholinesterase inhibitors, anti-muscarinic drugs, and 
Succinylcholine.  Its use in the pediatric patients, elderly patients, and patients 
with co-existing cardiac, pulmonary, hepatic, renal, and neuromuscular diseases 
appear to be safe and effective.  Sugammadex is dose-dependent, and it is up to 
the anesthetist to provide both adequate dosing and careful monitoring to ensure 
the complete reversal of a neuromuscular blockade.  While overdosing appears 
to be safe, inadequate dosing results in the recurrence of a blockade.   
 With proper use, Sugammadex addresses the need for a safe and 
effective reversal agent for patients, who will not safely tolerate Glycopyrrolate, 
Atropine, and Succinylcholine.  With Sugammadex, we are no longer forced to 
administer Succinylcholine in rapid sequence induction and difficult airway 
scenarios.  With Sugammadex, anesthetists will no longer feel reluctant to 
provide the surgeon with a profound neuromuscular blockade due to the difficulty 
in reversing the patient in a timely manner at the end of surgery.  The improved 
surgical conditions and predictability of Sugammadex will benefit both the 
surgeon and anesthetist.   
Future Plans 
 Due to the high cost of Sugammadex, it is not cost effective to implement 
Sugammadex as a drug for routine use.  It is, however, recommended that 
Sugammadex should be used for the reversal of profound blockades induced by 
Rocuronium or Vecuronium due the reduced staff cost from a shorter patient stay 
in recovery.  It is also recommended over conventional drugs if a patient’s 
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hemodynamic, pulmonary, or parasympathetic stability is desired.  While its 
routine use over Succinylcholine will always be beneficial, it is ultimately up to 
each institution to decide if the reduced risk of morbidity and mortality justifies its 
cost. 
 If Sugammadex becomes available for us in the United States, further 
study must ensure its safety in various patient profiles.  Healthcare providers 
must revisit proper patient monitoring to ensure an adequate dosage of 
Sugammadex had been given to the patient.  Reversing a profound blockade will 
be a novelty in our current practice, and anesthetists will need proper training to 
avoid inadequate reversal and recurarization.  There are potential benefits of 
Sugammadex that may provide different ways of managing the anesthetic care of 
the patient.  This includes its safety profile, increased predictability of reversal, 
and shorter recovery resulting in better use of the staff’s time and resources.  
These areas are the least explored in the current literature, and will probably 
require its adoption in clinical practice before all potential benefits of 
Sugammadex can be realized.   
 Further research in Sugammadex include, but not limited, to collecting 
data on its effects to better predict a patient’s recovery and potential adverse 
effects associated with the patient’s medical history.  Effectiveness, cost, and 
mortality rates from replacing Succinylcholine for rapid sequence induction can 
be further evaluated.  Pediatric and obstetric use of Sugammadex can be further 
investigated.  Finally, research on using Sugammadex in combination with 
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various anesthetics and analgesics will ultimately help the optimization of multiple 
anesthetic approaches.  This will help tailor the anesthetic management to each 
patient and surgeon’s needs. 
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